This perspective aims to provide an overview of the current understanding of tryptophan-AhR signaling in MASLD, discussing its potential as a therapeutic target and the challenges associated with targeting this pathway. The gene discussed is AHR; the disease is metabolic dysfunction-associated steatotic liver disease.